Papa John's International, Inc. (PZZA)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 11 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $51.73, which forecasts a 17.57% increase in the stock price over the next year. The lowest target is $38 and the highest is $71.

Price Target: $51.73 (+17.57%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$38	$51.73	$50	$71
Change	-13.64%	+17.57%	+13.64%	+61.36%

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	3	3	3	3	3	3
Buy	3	3	3	3	3	3
Hold	6	6	6	6	6	6
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Dennis Geiger UBS	UBS	Hold Maintains $38 → $42	Hold	Maintains	$38 → $42	-4.55%	Aug 4, 2025
Jim Salera Stephens & Co.	Stephens & Co.	Buy Reiterates $50	Buy	Reiterates	$50	+13.64%	Jun 12, 2025
Todd Brooks Benchmark	Benchmark	Strong Buy Reiterates $50	Strong Buy	Reiterates	$50	+13.64%	May 12, 2025
Alton Stump Loop Capital	Loop Capital	Strong Buy Maintains $60 → $56	Strong Buy	Maintains	$60 → $56	+27.27%	May 9, 2025
Jim Salera Stephens & Co.	Stephens & Co.	Buy Reiterates $50	Buy	Reiterates	$50	+13.64%	May 9, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.15B

Increased by 4.35%

from 2.06B

Revenue Next Year

2.22B

Increased by 3.30%

from 2.15B

EPS This Year

1.74

Decreased by -31.50%

from 2.54

EPS Next Year

2.29

Increased by 31.41%

from 1.74

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 27, 2020	Dec 26, 2021	Dec 25, 2022	Dec 31, 2023	Dec 29, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.81B	2.07B	2.10B	2.14B	2.06B	2.15B	2.22B	2.26B
Revenue Growth	11.98%	14.07%	1.63%	1.60%	-3.57%	4.35%	3.30%	1.62%
EPS	1.28	0.12	1.89	2.48	2.54	1.74	2.29	2.78
EPS Growth	-	-90.91%	1,524.44%	31.22%	2.42%	-31.50%	31.41%	21.80%
Forward PE	-	-	-	-	-	25.29	19.25	15.80
No. Analysts	-	-	-	-	-	18	18	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	2.2B	2.3B	2.4B
Avg	2.1B	2.2B	2.3B
Low	2.0B	2.1B	2.1B

Revenue Growth

Revenue Growth	2025	2026	2027
High	8.8%	8.9%	6.6%
Avg	4.4%	3.3%	1.6%
Low	-0.7%	-2.9%	-4.2%

EPS Forecast

EPS	2025	2026	2027
High	2.08	2.57	2.94
Avg	1.74	2.29	2.78
Low	1.51	2.06	2.61

EPS Growth

EPS Growth	2025	2026	2027
High	-18.1%	47.9%	28.6%
Avg	-31.5%	31.4%	21.8%
Low	-40.6%	18.3%	14.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.